Korea S.E.
23:00:00 30/05/2024 BST
5-day change
1st Jan Change
8,750
KRW
-0.57%
-3.95%
+26.81%
03-27
Polaris Office Corp., Leenos Corp., Sewon Co.,Ltd and POLARIS UNO, Inc. completed the acquisition of 20% stake in EstechPharma Co., Ltd. from Jae-cheol Kim and Seon-hee Bae.
CI
02-29
Polaris Office Corp., Leenos Corp., Sewon Co.,Ltd and POLARIS UNO, Inc. agreed to acquire 20% stake in EstechPharma Co., Ltd. from Jae-cheol Kim and Seon-hee Bae for KRW 40 billion.
CI
Tranche Update on EstechPharma Co., Ltd.'s Equity Buyback Plan announced on December 12, 2016.
June 12, 2017 at 09:15 am
From January 1, 2017 to June 12, 2017, the company has repurchased 68,192 shares, representing 0.6% for KRW 676.41 million. With this, the company has completed the repurchase of 106,086 shares, representing 0.94% for KRW 1,054.08 million under the buyback announced on December 12, 2016.
Polaris Office Corp., Leenos Corp., Sewon Co.,Ltd and POLARIS UNO, Inc. completed the acquisition of 20% stake in EstechPharma Co., Ltd. from Jae-cheol Kim and Seon-hee Bae.
03-26
CI
Polaris Office Corp., Leenos Corp., Sewon Co.,Ltd and POLARIS UNO, Inc. agreed to acquire 20% stake in EstechPharma Co., Ltd. from Jae-cheol Kim and Seon-hee Bae for KRW 40 billion.
02-28
CI
EstechPharma Co., Ltd.(KOSDAQ:A041910) dropped from S&P Global BMI Index
23/09/19
CI
Vivozon Inc. announced that it has received KRW 100 billion in funding from TELCON RF PHARMACEUTICAL. Inc., EstechPharma Co., Ltd.
24/05/18
CI
Vivozon, Inc. announced that it expects to receive KRW 100 billion in funding from TELCON RF PHARMACEUTICAL. Inc., EstechPharma Co., Ltd.
18/03/18
CI
Tranche Update on EstechPharma Co., Ltd.'s Equity Buyback Plan announced on December 12, 2016.
12/06/17
CI
EstechPharma Co., Ltd.'s Equity Buyback announced on December 12, 2016, has expired with 106,086 shares, representing 0.94% for KRW 1,054.08 million.
11/06/17
CI
Tranche Update on EstechPharma Co., Ltd.'s Equity Buyback Plan announced on December 12, 2016.
13/03/17
CI
EstechPharma Co., Ltd. authorizes a Buyback Plan.
11/12/16
CI
EstechPharma Co., Ltd. announces an Equity Buyback for KRW 3,000 million worth of its shares.
11/12/16
CI
EstechPharma Co., Ltd.(KOSDAQ:A041910) added to S&P Global BMI Index
21/09/15
CI
Vivozon, Inc. announced that it has received KRW 2 billion in funding from EstechPharma Co., Ltd.
05/12/14
CI
Vivozon, Inc. announced that it expects to receive KRW 2 billion in funding from EstechPharma Co., Ltd.
02/12/14
CI
Tranche Update on EstechPharma Co., Ltd.'s Equity Buyback Plan announced on December 5, 2013.
30/12/13
CI
EstechPharma Co., Ltd.'s Equity Buyback announced on December 5, 2013 has closed with 110,619 shares for KRW 950.06 million.
30/12/13
CI
EstechPharma Co., Ltd. announces an Equity Buyback for 110,619 shares, for KRW 1,000 million.
04/12/13
CI
EstechPharma Co., Ltd. authorizes a Buyback Plan.
04/12/13
CI
Korea Securities Finance Corporation acquired 4.06% stake in EstechPharma Co., Ltd..
10/10/13
CI
Estechpharma Co. Ltd. announced that it has received KRW 4 billion in funding.
10/04/12
CI
Estechpharma Co. Ltd. announced that it expects to receive KRW 4 billion in funding.
06/04/12
CI
Duration Auto. 2 months 3 months 6 months 9 months 1 year 2 years 5 years 10 years Max.
Period Day Week
More charts
Polaris AI Pharma Corp, formerly ESTECHPHARMA CO., LTD, is a Korea-based company engaged in the development and manufacture of pharmaceuticals. The Company is engaged in the manufacture and sale of peptic ulcer medicine, diabetes medicine, central nervous system medicine, antispasmodics, antipyretics, and painkillers. It has a research and development institute that develops active pharmaceutical ingredients. The company sells its products in domestic and international markets.
More about the company
1st Jan change
Capi.
+26.81% 73.9M +40.73% 739B +32.83% 598B -6.30% 353B +15.15% 318B +4.05% 285B +15.00% 240B -5.52% 206B +6.17% 164B -0.45% 162B
Other Pharmaceuticals
+951% of historical
More than 20 years
Our Experts
OUR EXPERTS ARE HERE FOR YOU
Monday - Friday 9am-12pm / 2pm-6pm GMT + 1
POLARIS AI PHARMA CORP. 
